What do the screening trials really tell us and where do we go from here?

Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol (2015) 2.20

Quantifying Gleason scores with photoacoustic spectral analysis: feasibility study with human tissues. Biomed Opt Express (2015) 0.82

The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. Nat Rev Urol (2016) 0.81

Clonal evaluation of prostate cancer foci in biopsies with discontinuous tumor involvement by dual ERG/SPINK1 immunohistochemistry. Mod Pathol (2016) 0.77

Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94

Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05

Prostate-cancer mortality at 11 years of follow-up. N Engl J Med (2012) 16.91

Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2012) 15.83

Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol (2010) 12.64

Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14

Quality-of-life effects of prostate-specific antigen screening. N Engl J Med (2012) 7.21

American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin (2010) 6.45

Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med (2013) 4.45

Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ (2013) 3.51

Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int (2008) 3.51

Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol (2009) 3.42

Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. J Urol (2005) 3.01

What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? J Clin Oncol (2010) 2.49

Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. J Clin Epidemiol (2011) 2.46

Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer. Eur Urol (2013) 2.43

Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials (2010) 2.38

Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer (2007) 2.31

Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening. Med Care (2013) 1.88

The story of the European Randomized Study of Screening for Prostate Cancer. BJU Int (2003) 1.55

The impact of PLCO control arm contamination on perceived PSA screening efficacy. Cancer Causes Control (2012) 1.36

Commentary on "prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: Mortality results after 13 years of follow-up". Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hsing AW, Izmirlian G, Pinsky PF, Kramer BS, Miller AB, Gohagan JK, Prorok PC; PLCO Project Team.Collaborators (18) Buring JE, Alberts D, Carter HB, Chodak G, Hawk E, Malm H, Mayer RJ, Piantadosi S, Silvestri GA, Thompson IM, Westhoff CL, Kahn JP, Levin B, DeMets D, O'Fallon JR, Porter AT, Ashton MM, Black WC, Division of Urologic Surgery, Washington University School of Medicine, St. Louis, MO 63130, USA: J. Natl Cancer Inst 2012; 104(2):125-32. Epub January 6, 2012. Urol Oncol (2012) 1.14

Quality of life and guidelines for PSA screening. N Engl J Med (2012) 1.12

Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening. BJU Int (2003) 1.07

Prostate cancer mortality in the Finnish randomized screening trial. J Natl Cancer Inst (2013) 1.01

Mortality reductions produced by sustained prostate cancer screening have been underestimated. J Med Screen (2010) 0.99

Measuring mortality reductions in cancer screening trials. Epidemiol Rev (2011) 0.91